Steven M. Chaouki - 22 Dec 2025 Form 4 Insider Report for MAIA Biotechnology, Inc. (MAIA)

Reporting relationship: Director
Issuer ticker: MAIA
Reported as of: 22 Dec 2025
Net transaction value: +$105,554
SEC form: 4
Accepted by SEC: 23 Dec 2025, 08:16:48 UTC
Prior SEC filing: 02 Dec 2025
Next SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Steven M. Chaouki

Key filing fact

Steven M. Chaouki filed Form 4 for MAIA Biotechnology, Inc. (MAIA) on 23 Dec 2025.

Key facts

This page summarizes Steven M. Chaouki's Form 4 filing for MAIA Biotechnology, Inc. (MAIA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Dec 2025, 08:16.

Change

Previous filing in this sequence was filed on 02 Dec 2025.
Current net transaction value: +$105,554.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001776865 Primary reporting owner

CHAOUKI STEVEN M

Relationship: Director
Address: 444 WEST LAKE STREET, SUITE 1700, CHICAGO
Signature: /s/ Steven M. Chaouki
Signature date: 22 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MAIA transaction

Common Stock

Purchase

Transaction value: $49,999
Shares: +40,849
Change %: +37%
Price: $1.22
Shares after: 151,873
Date: 22 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAIA transaction Derivative

Stock Options

Purchase

Transaction value: $55,555
Shares: +40,849
Change %
Price: $1.36
Shares after: 40,849
Date: 22 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,849
Exercise price: $1.36
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The common stock was purchased pursuant to a Securities Purchase Agreement and were issued under the Issuer's 2021 Equity Incentive Plan on December 22, 2025.

Footnote F2

These warrants were purchased pursuant to a Securities Purchase Agreement and were deemed options under the Issuer's 2021 Equity Incentive Plan on December 22, 2025. The options are exercisable beginning on the six month anniversary of the issuance date and expire 3-years after the initial issuance date.